HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5787
Abstract: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect… read more here.
Keywords: plus tyrosine; kinase inhibitor; immunotherapy plus; tyrosine kinase ... See more keywords